Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Inclusion Criteria:

Participants must meet all of the following criteria:

* Male or Female patients 18 years and older.
* Patient with a diagnosis of chronic myelogenous leukemia in chronic phase
* Within 6 months of initial diagnosis.
* Received any treatment for CML for less than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.

Exclusion Criteria:

* Late chronic phase, accelerated phase or blastic phase
* Taking any other investigational agents within 28 days of starting the study
* If sibling donors have been identified and where allogeneic bone marrow transplantation will be the first line treatment.
* Another primary malignancy /cancer unless it is not considered clinically significant or does not require active intervention.
* If patients have heart problems or complications
* Pregnant or breast-feeding females
* Severe and/or uncontrolled disease such as diabetes, chronic renal disease, etc.
* Chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
* Diagnosis of human immunodeficiency virus (HIV) infection.
* Received any treatment for CML for longer than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.
* Patient previously received radiotherapy to greater than 25% of the bone marrow.
* Patient had a major surgery within 4 weeks prior to study entry